Sugi Predict

Sugi Predict / Compounds / SCHEMBL20147575

SCHEMBL20147575

SCHEMBL20147575

CC(C)N1CCC(C)(NC(=O)c2ccccc2S(C)(=O)=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BCAT2 O15382 1/20 0.47
▸ RET P07949 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ HCN4 Q9Y3Q4 3/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ P2RX7 Q99572 1/20 0.38
▸ CCR3 P51677 3/20 0.38
▸ HRH1 P35367 2/20 0.38
▸ HCN1 O60741 2/20 0.38
▸ MMP1 P03956 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ TRPV4 Q9HBA0 1/20 0.37
▸ EED O75530 1/20 0.37
▸ PABPC1 P11940 1/20 0.37
▸ EIF4H Q15056 1/20 0.37
▸ PARP1 P09874 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206058 0.90 BCAT2 (0.45) BCAT2RETLMNAP2RX7CCR3
SCHEMBL20068935 0.86 BCAT2 (0.50) BCAT2RETLMNAP2RX7CCR3
SCHEMBL20068953 0.83 P2RX7 (0.47) HCN4CYP2D6P2RX7HCN1
SCHEMBL20158434 0.82 BCAT2 (0.47) BCAT2RETLMNAHCN4P2RX7
SCHEMBL20147551 0.82 P2RX7 (0.47) HCN4P2RX7
SCHEMBL20147572 0.82 GAA (0.45) HCN4CYP2D6CCR3HCN1
SCHEMBL20147580 0.81 HCN4 (0.57) RETHCN4CYP2D6P2RX7CCR3
SCHEMBL20147583 0.80 HCN1 (0.57) HCN4HCN1
SCHEMBL20147582 0.79 RET (0.43) RETLMNAHCN4CYP2D6HCN1
SCHEMBL20147652 0.79 P2RX7 (0.48) RETHCN4P2RX7HCN1TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 — — US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 — — US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 — — US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 — — US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 BCAT2 3424/4885RET 1/4885LMNA 1968/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 BCAT2 3424/4885RET 1/4885LMNA 1968/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 BCAT2 3424/4885RET 1/4885LMNA 1968/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 BCAT2 3424/4885RET 1/4885LMNA 1968/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 BCAT2 3424/4885RET 1/4885LMNA 1968/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 BCAT2 3424/4885RET 1/4885LMNA 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.